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Abstract: Qualitative and quantitative methods for the analysis of opiates on the liquid 
chromatograph-tandem mass spectrometer (LC/MS/MS) were developed and validated. 
The qualitative method was developed for the analysis of seven opiate compounds: 6-
acetylmorphine (6-MAM), codeine, hydrocodone, hydromorphone, morphine, 
oxycodone, and oxymorphone. A quantitative method was developed for the quantitation 
of four opiate compounds: codeine, hydrocodone, morphine, and oxycodone.  The 
validation was based on draft forensic validation Blood specimens were prepared using a 
dilute and shoot (D&S) method and a solid phase extraction (SPE) method. While the 
comparison data showed that the SPE was more sensitive for the analysis of opiates, the 
D&S method also produced accurate and reliable results at the levels required for 
forensic purposes 
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CHAPTER I 
 
 
INTRODUCTION 
 
Opiates, naturally occurring alkaloid analgesics, are the most abused drugs in 
every socioeconomic level in today’s society. These compounds have the ability to 
provide analgesia without loss of consciousness. The common effects are described as 
euphoria, sedation, and mental clouding. Opioid tolerance after chronic use can result in 
overdosing to feel the beneficial effects. Despite being highly addictive, these drugs are 
commonly prescribed for pain relief after surgeries or for chronic pain. As a result of 
frequent abuse, identifying opiates has become increasingly demanded in suspected 
driving under the influence of drugs (DUID) cases. [1-4]
 
 
There are several possible liquid chromatography-tandem mass spectrometry (LC-
MS/MS) sample preparation methods employed in forensic laboratories to determine if 
an individual was under the influence of drugs while driving, including solid phase 
extraction (SPE), liquid-liquid extraction (LLE), and dilute and shoot (D&S) techniques. 
While the SPE method is considered more labor intensive and requires costly materials 
such as columns, it is considered to give cleaner extracts and better results. The LLE is a 
less expensive option and is potentially less labor intensive, depending how many
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steps are required. The D&S method is the most rapid method because it skips the 
extraction process completely, although filtration may be required. [5] For state crime 
laboratories that are on a budget and have backlog, it is appealing to determine whether 
cheaper and quicker sample preparation methods may yield comparable results to SPE 
using the LC/MS/MS. 
 Recently published reviews of the literature have compiled various extraction 
methods into tables. The methods are usually separated by sample matrix (blood, urine, 
serum and hair) and by analytical instrument. The main analytical instruments employed 
are the gas chromatography-mass spectrometer (GC-MS) and the liquid chromatography-
mass spectrometer (LC-MS). Most of the reviews cover a wide variety of drugs and are 
not specific to opiates. Methods specific for opiates were analyzed for only one or two 
opiate compounds. Often the papers reviewed lacked information needed for comparative 
purposes, such as linearity, limit of quantification (LOQ) and limit of detection (LOD).[1, 
5-7]
  
Two analytical methods for the analysis of opiates on the LC/MS/MS were 
developed at the Oklahoma State Bureau of Investigation (OSBI). The qualitative method 
was developed for the analysis of seven opiate compounds: 6-acetylmorphine (6-MAM), 
codeine, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone. A 
quantitative method was developed for the quantitation of four opiate compounds: 
codeine, hydrocodone, morphine, and oxycodone. The samples to be analyzed by 
LC/MS/MS were prepared using a D&S method. Both the qualitative and quantitative 
methods were validated at the OSBI lab. [8] 
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For the comparison study, samples were prepared using either SPE or D&S, and then 
analyzed by the quantitative LC/MS/MS method .The results were compared to 
determine which extraction method yielded better results. The goal of this study was to 
show demonstrate that the D&S method yields results with sufficient quality to avoid 
costly SPE preparation methods for the analysis of opiates. It would encourage future 
research to focus on cheaper and less time-consuming methods for other illicit drugs.
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
2.1 Overview 
Opiates, naturally occurring alkaloid analgesics, are the most abused drugs in 
every socioeconomic level in today’s society. Although the term opiate is used to refer to 
any compound derived from the poppy plant, Papaver somniferum, compounds that are 
naturally derived from opium are considered opiates, while compounds that are 
synthetically created are referred to as opioids. These compounds have the ability to 
provide analgesia without loss of consciousness. The common effects are described as 
euphoria, sedation and mental clouding. Opioid tolerance after chronic use can result in 
overdosing to feel the beneficial effects. Overdosing can lead to death through the 
suppression of respiratory drive. Despite being highly addictive, these drugs are 
commonly prescribed for pain relief after surgeries or for chronic pain. As a result of 
frequent abuse, identifying opiates has become increasingly demanded in suspected 
driving under the influence of drugs (DUID) cases. Use of opiates are known to affect 
driving in the following ways: slow driving, weaving, poor vehicle control, poor 
coordination, slow response to stimuli, delayed reactions, difficulty following instructions 
and falling asleep at the wheel.[1-4] 
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There is an abundance of literature specific to opiate analysis due to the combined 
efforts of clinical and forensic researchers. The main analytical instruments employed are 
the gas chromatography-mass spectrometer (GC-MS) and the liquid chromatography-
mass spectrometer (LC-MS), with an increasing focus on the LC-MS. The most common 
sample preparation methods utilized are solid phase extraction (SPE), liquid liquid 
extraction (LLE), and dilute and shoot (D&S) techniques.[1-4] With all the literature 
available, a review of opiate compounds, DUID legislature, and LC/MS/MS 
instrumentation was conducted. In addition, a comparison of analytical instruments, 
sample preparation methods and chromatographic conditions was performed to determine 
which sample preparation protocol produces better results.  
2.1 Opiates 
Seven opiates and opioids were reviewed in this study, including: codeine, heroin, 
hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone. Their chemical 
structures are shown in Figure 1. 
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a.  b.  
c.  d.  
e.  f.  
g.  h.  
Figure 1. Chemical Structures of Opiates  
The chemical structures of 6-MAM, codeine, heroin, hydrocodone, hydromorphone, 
morphine, oxycodone and oxymorphone are listed in a-h, respectively. Images from 
Lewis et al., Quary et al., and Capella-Peiro et al.  [9-11] 
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2.1.1 Codeine 
Codeine, a semisynthetic narcotic agonist, is naturally occurring in the juice of the 
poppy plant. It is created commercially by the methylation of morphine. Codeine is 
considered a low-potency analgesic, being approximately 1/10 to 1/6 as potent as 
morphine. It is metabolized by demethylation to morphine and norcodeine. Therapeutic 
doses found in toxicological samples range from 10 to 100 ng/ml. The wide range is due 
to the body building up tolerance to the drug, which makes higher concentrations of the 
drug necessary for any therapeutic effects. This opiate is often sold in over-the-counter 
medicines in combination with other non-opioid analgesics like aspirin or acetaminophen 
in the form of phosphate or sulfate salts. Adverse side-effects include nausea, vomiting, 
sedation, dizziness, rash, respiratory depression. [4] The chemical structure of codeine is 
shown in Figure 1.  
2.1.2 Heroin 
Heroin is synthesized from morphine and is currently a Schedule I substance in 
the United States. It currently has no known accepted medical use and is usually 
administered as the hydrochloride salt for intravenous injection or by nasal insufflation. 
The illicit compound undergoes deacetylation to 6-monoacetylmorphine (6-MAM), 
which is in turn hydrolyzed to morphine. The presence of 6-MAM with morphine is 
conclusive evidence of heroin use, because heroin is the only compound that metabolizes 
to 6-MAM.[4] The chemical structure of heroin and its metabolite 6-MAM are shown in 
Figure 1. 
2.1.3 Hydrocodone 
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Hydrocodone is a semisynthetic narcotic analgesic agonist derived from codeine. 
It is considered to have 6 times the analgesic potency of codeine and a greater addiction 
liability. Therapeutic doses found in toxicological samples range from 2 to 24  ng/ml. It is 
usually administered as the bitartrate salt in combination with non-opioid analgesics and 
is widely present in cough syrup. The toxic effects include stupor, muscle flaccidity, 
respiratory depression, cold and clammy skin, and coma. While it is excreted as mostly 
unchanged drug, it does undergo demethylation to produce norhydrocodone, and 
hydromorphone.[4] The chemical structure of hydrocodone is shown in Figure 1. 
2.1.4 Hydromorphone 
Hydromorphone, a semisynthetic narcotic analgesic agonist, is a metabolite of 
hydrocodone. It is approximately 7 to 10 times more potent than morphine, but it is 
similar in addiction liability. Therapeutic doses found in toxicological samples range 
from 1 to 30 ng/ml. It is supplied as the hydrochloride salt and is commonly used in 
cough syrup. It undergoes conjugation to produce conjugated hydromorphone and 
conjugated hydromorphol.[4] The chemical structure of hydromorphone is shown in 
Figure 1. 
2.1.5 Morphine 
Morphine is the principle alkaloid of opium. It is a popular drug for moderate to 
severe pain. Therapeutic doses found in toxicological samples range from 10 to 80 ng/ml. 
The wide range is due to the body building up tolerance to the drug which makes higher 
concentrations of the drug necessary for any therapeutic effects. It is often supplied as the 
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sulfate salt for perinatal injection. It is metabolized by undergoing demethylation to 
normorphine.[4] The chemical structure of morphine is shown in Figure 1. 
2.1.6 Oxycodone 
Oxycodone, a semisynthetic narcotic agonist, is derived from thebaine. It is used 
for the relief of moderate to severe pain. Given subcutaneously, the drug is equipotent 
with morphine, but it has a higher oral/parenteral efficacy ratio. It is frequently used in 
combination with non-opioid analgesics as the hydrochloride or terephthalate salt. The 
compound undergoes demethylation, 6-keto reduction and conjugation to oxymorphone 
and noroxycodone. Therapeutic doses found in toxicological samples range from 10 to 
100 ng/ml. The wide range is due to the body building up tolerance to the drug which 
makes higher concentrations of the drug necessary for any therapeutic effects.  [4]
 
The 
chemical structure of oxycodone is shown in Figure 1. 
2.1.7 Oxymorphone 
Oxymorphone, a metabolite of oxycodone, is a semisynthetic narcotic opiate 
agonist, also derived from thebaine. The compound is used for the relief of moderate to 
severe pain and for preoperative medication. It has about 6 to 8 times the analgesic 
potency of morphine. It is often supplied as the hydrochloride salt through oral dosing or 
parenteral injection. Oxymorphone undergoes extensive metabolism by reduction and 
conjugation to produce conjugated oxymorphone and 6-β-oxymorphol.[4] The chemical 
structure of oyxmorphone is shown in Figure 1.  
2.2 DUID legislature 
2.2.1 Per se law 
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Per se laws are implemented in an effort to deter drunk or drugged driving. These 
laws make it an offense to drive with a drug concentration past a set limit. The per se law 
is most commonly implemented for the detection of alcohol. Without per se laws for 
drugs, most of the evidential basis for a conviction for drugged driving is based on 
behavioral observations. Behavioral observations of impairment are often vague and 
easily challenged in courts. The zero tolerance law makes it an offense to drive with a 
certain drug at any detectable amount. This is often seen for alcohol present in 
individuals under the legal drinking age of 21. Studies on the effects of these laws have 
found that there are some beneficial effects on traffic safety. This may be due to general 
deterrence, where someone who might otherwise drink and drive are deterred from doing 
so due to knowledge of the law and resulting repercussions by violating it. [12, 13] 
2.2.2 Oklahoma 
The Oklahoma statues for driving under the influence (DUI) of alcohol or 
intoxicating substances (47 O.S. §,11-902) states that it is unlawful and punishable to 
have a breath or blood alcohol concentration of 0.08 or more within two hours after an 
arrest. It is unlawful to have any amount of a Schedule I chemical present in a person’s 
system within two hours after an arrest. It is also unlawful to have any controlled 
substance present in a person’s system within two hours after an arrest, meaning a 
Schedule II or III chemical without a physician’s prescription.  If an officer suspects DUI 
and any intoxicating substance is detected (level not specified), then the individual is in 
violation of the statute. 
2.3 Sample preparation method 
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Sample preparation methods are employed for purposes of removing potential 
interferents from the sample, increasing the amount of the analyte recovered, converting 
the analyte into a more suitable form for detection/separation, providing a robust and 
reproducible method for dependable analysis. [14] 
2.3.1 Solid Phase Extraction 
SPE is a frequently used sample preparation method in toxicology laboratories. 
SPE involves column conditioning, sample application, column washing, column drying, 
and analyte elution. [15] The SPE column is a material-packed cartridge and there is a 
large variety available for specific trapping mechanisms of the analyte. Polarity, 
hydrophobicity, or ionization are often used as trapping mechanisms on the column, 
which requires matrix pH modifications to make the analyte either non-polar or aqueous. 
The trapped analyte is then released from the column by altering the polarity or pH in an 
eluting solvent. [14] 
The benefit of using SPE columns is the wide variety of columns available and 
numerous methods with several combinations of cartridge material combined with 
eluent/sample matrices available in the literature. The use of disposable SPE columns 
minimizes the biohazard risk by reducing the handling of body fluids, such as urine, 
plasma, and blood. While the consumable cost of single-use cartridges and filters is quite 
a considerable amount, it may be more cost-effective than purchasing chemicals 
necessary for other sample preparation methods like LLE. The SPE method is considered 
more labor intensive, but it considered to yield cleaner extracts and better results.[5, 14] 
2.3.2 Liquid-liquid extraction 
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LLE is also a frequently used sample preparation method in toxicology 
laboratories. LLE involves adjusting the pH of a liquid sample with a buffer, acid, or base 
and then extracting analytes with an organic solvent. Back extraction may also be used to 
remove the analyte from the organic solvent to further increase selectivity and sensitivity. 
[14, 15]  
The benefit of using the LLE sample preparation method is the vast amount of 
literature available, which provides information on organic solvents and on the pH type, 
and concentration of reagents.[16] The LLE is a less expensive option and is potentially 
less labor intensive, depending on how many steps are required.[5]
 
2.3.3 Dilute and shoot 
The D&S sample preparation method involves protein precipitation by diluting a 
sample with an organic solvent, such as acetonitrile. It is the fastest method, because it 
skips the extraction process altogether. In the literature, this sample preparation method is 
known to experience matrix effects during LC-MS analysis. There is minimal cleanup of 
the biological samples due to the non-selective nature of the D&S method. While it is one 
of the least labor intensive methods, the results may be affected due to inadequate sample 
cleanup.[5, 17] 
 
2.4 Analytical Instrument Comparison 
Within the last few decades, there have been tremendous technological 
advancements in the field of mass spectrometry (MS), resulting in the integration of the 
LC-MS in toxicological analysis.[1] Use of the LC-MS is favored over use of the gas 
chromatography-mass spectrometry (GC-MS) because of its increased sensitivity and 
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specificity.[2] In the recent literature, researchers have compared the LC-MS opiate 
method developed to a former GC-MS opiate method.  
 Sample preparation is necessary to remove interfering matrix compounds; thereby 
improving both selectivity and sensitivity.[1] Overall, the LC-MS has a simpler sample 
preparation protocol and allows the exclusion of steps that are otherwise necessary for the 
GC-MS. Coles et al. developed a LC-MS method for the simultaneous analysis of six 
opiates in various specimens. The sample preparation for the LC-MS excluded the 
derivitization and glucuronide hydrolysis necessary in the described GC-MS sample 
preparation. The reduction of steps in the sample preparation dramatically reduced 
extraction time and use of expensive eluents.[2]
 
 Gustavsson et al. described a sample preparation procedure for the LC-MS which 
involved a straight injection of the urine specimen for the analysis and quantification of 
morphine, codeine and 6-MAM.[18] This is much simpler than the multi-step preparation 
necessary for the GC-MS, which included hydrochloric acid hydrolysis, solid-phase 
extraction and the formation of silyl derivatives.
 
Most of the literature shows that the LC-MS method developed is comparable to 
the GC-MS analysis in accuracy and precision. In qualitative methods, both of these 
instruments were in agreement with regard to the identification of drug analytes. But in 
quantitative methods, the LC-MS method was even more sensitive and selective.[1, 18, 
19] In the Coles et al. article, the LC-MS had a 100-fold increase in analytical sensitivity 
with the lower limit of quantitation of 2.0 ng/ml, while the GC-MS had a lower limit of 
quantitation at 200 ng/ml. The LC-MS method had an increased specificity with an 
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interference rate of 3.9% compared to the higher interference rate of 13.6% for the GC-
MS method.[2] 
2.5 Sample Preparation Comparison 
Coles et al. described a SPE method for use with urine, serum, plasma, and whole 
blood. To 1.0 mL of specimen, 2.0 mL of 0.1M sodium phosphate buffer was added. The 
sample was mixed and then centrifuged at 0°C, 3500 rpm for five minutes. The samples 
were loaded onto Trace-B columns at 4 drops/s and washed with 1 ml each of sodium 
bicarbonate buffer, water, 0.1M acetic acid, methanol, and ethyl acetate at 1 drops/s. The 
columns were dried at 25 psi for a minute and then the samples were eluted into recovery 
vials with 1 ml of a 70:25:5 mixture of ethyl acetate/isopropanol/ammonium hydroxide. 
These samples were dried down at 40°C for 12 minutes, reconstituted with 200μL 
acetonitrile and analyzed on the LC-MS.[2] 
Cailleux et al. described an LLE method that was used for urine, plasma and 
blood. First, 25 μL of 2.5 mg/L internal standards were added to 250 μL of specimen. 
Then, 100 μL of 1M ammonia buffer and 1.25 mL of CHCl3/isopropanol (95:5) mixture 
were added to the specimen, which was then rotated and centrifuged for 10 minutes. The 
organic phase was dried down and reconstituted in a 5:1 mixture of water/acetonitrile.[6]
 
In comparing the quantitative results, the SPE method has a lower limit of 
quantitation at 2.0 ng/ml, while the LLE method had a lower limit of 10 μg/ml. Because 
the SPE method involves a multiple-step washing process, the specimen analyzed is 
theoretically cleaner than the LLE specimen.[2, 6]
 
2.5.1 Sample preparation of blood, serum and plasma 
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Musshoff et al. described a type of SPE method for plasma specimens. First, 1.96 
ml of a pH 9 buffer and 40 uL of the internal standards were added to 1 ml of plasma. 
The sample was then extracted using the Caliper Life Sciences Rapid Trace Workstation, 
which involved conditioning the column, loading the sample, washing the column and 
air-drying the column. The sample was then eluted and collected off the column. The 
collected sample was dried down and reconstituted.[20]
 
Bouzas et al. described an LLE method for serum specimens. Protein precipitation 
was performed by adding 200 μL of a 4:1 mixture of methanol/zinc sulphate (0.1 M) to 
100 uL of serum. The specimen was then centrifuged at 13,200 rpm for 10 minutes and 
the supernatant was evaporated to dryness at 40°C. The specimen was then reconstituted 
in 100 μL of 0.1% formic acid and analyzed.[19] 
The results of sample preparation specific to blood, serum, and plasma specimens 
differed from the general specimen sample preparation methods discussed in the last 
section. In serum and plasma, the LLE method has a lower limit of quantitation that 
varies from 0.5 to 2.8 ng/ml. The lower limit of quantitation for the SPE method varied 
from 1.0 ng/ml to 10 ng/ml.[19, 20]
 
2.5.2 Sample preparation of urine 
Most of the sample preparation methods found for specimens in urine were 
created for the clinical purpose of identifying drug abuse in patients. The sample 
preparations described were very simple LLE methods. Shakleya et al. mixed 100 μL of 
urine by vortexer and centrifuged the sample for five minutes to remove larger particles. 
Then 10 μL of the supernatant was placed into injection vials and analyzed. Researchers 
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found that the lower limit of quantitation was at 10 to 100 μg/ml.[11] Gustavsson et al. 
described a similar LLE method that involved mixing 20 μl of urine with 80μl of internal 
standard solution. The lower limit of quantification was much lower than the Shakleya et 
al. article, with a variation from 1.0 ng/ml to 126 ng/ml.[18, 21]
 
2.6 Chromatographic conditions 
 Chromatographic conditions of the LC can drastically alter the results of a drug 
analysis. Column and eluent selection are the most variable aspects in effecting 
chromatographic conditions.[5]
 
2.6.1 Type of column 
 Using the right type of column can shorten analysis time and improve 
chromatographic conditions. Controlling the temperature of the column assists in 
reproducible retention times of the drug analytes.[5] Many of the opiate methods 
described in the literature used Allure PFP or Phenomenex columns. Most were packed 
with anywhere from 3 μm to 5 μm particles, although Musshoff et al. used a Phenomenex 
column packed with 400 μm particles. The oven temperature ranged from 30°C to 
40°C.[2, 5, 18-20] There is most likely a lack of diversity concerning column types, 
because the Allure PFP and Phenomenex columns give consistent and reliable results.  
2.6.2 Eluents 
 Eluent composition used for the LC-MS method is chosen based on the mode the 
drugs are ionized in. The electrospray ionization (ESI) probe is more commonly used for 
positive mode and atmospheric pressure chemical ionization (APCI) is used more often 
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for negative mode, although this is not always the case. All the papers reviewed used ESI, 
possibly because it produced a stronger response than using APCI.[2, 5, 18-20, 22] When 
using the ESI mode, aqueous eluents with an additive concentration of less than 10 mM 
are recommended. A lower flow rate of 0.1 mL/min or less is also recommended to 
improve signal intensity on the LC-MS.[5]
 
 Most of the articles reviewed used a greater flow rate than 0.1 mL/min. Lower 
flow rates may increase sensitivity, but they take longer to analyze on the LC. Lower 
flow rates also tend to have poorer chromatography compared to higher flow rates. [4] 
Most methods included eluents with an additive concentration of formic acid or 
ammonium formate at less than 10 mM, except the Gustavsson et al. method.[2, 5, 18, 19, 
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that employed an eluent additive at a concentration of 25 mM, but the higher 
concentration did not noticeably affect results.[18]
 
2.7 Findings 
The LC-MS method specific to opiates is well-researched, with many studies 
conducted within the last fifteen years. Review of the literature has found that the use of 
the LC-MS has several advantages over the GC-MS for opiate methods. The sample 
preparation for the LC-MS is faster and uses less eluents. The LC-MS also produces 
more selective and sensitive results than the GC-MS. The chromatographic conditions 
employed in the literature did not vary much, with most methods using similar eluents 
and columns types. Most of these conditions are chosen specifically for the compounds 
being analyzed, so that would explain the lack of variation.  
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Most of the published literature reviewed covered a wide variety of drugs and was 
not specific to opiates. The methods that were specific to opiates only analyzed one or 
two opiate compounds. Often the papers reviewed were lacking the information needed 
for comparative purposes, such as linearity, limit of quantification (LOQ) and limit of 
detection (LOD).[1, 5-7]
 
While articles are available on the results of SPE and LLE sample preparation, the 
extraction methods seem to depend on the specimen type. There is not enough research to 
confidently determine which extraction method produces better results. Comparison 
studies are necessary to determine how different sample preparations and specimen types 
affect results.  
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CHAPTER III 
 
 
METHODOLOGY 
 
3.1 Introduction 
 At the OSBI in Edmond, Oklahoma, a qualitative and quantitative method for the 
liquid chromatograph-mass spectrometer (LC-MS) was developed for the analysis of 
opiates. The qualitative method was developed for the analysis of 6-acetylmorphine, 
codeine, hydrocodone, hydromorphone, morphine, oxycodone and oxymorphone. A 
quantitative method for the was developed for the analysis of codeine, hydrocodone, 
morphine, and oxycodone. A D&S sample preparation method for blood was developed 
and validated according to the protocols set by the OSBI. A SPE for the quantitative 
analysis of codeine, hydrocodone, morphine, and oxycodone in blood was developed for 
comparison to the D&S sample preparation method.  
3.2 Instrumentation 
 All samples were analyzed with a Shimadzu LC-MS instrument. The LC-MS-
8030 was equipped with the system controller CBM-20A, solvent delivery unit LC-
30AD, autosampler SIL-30AC, column oven CTO-20AC, and column Kinetex 2.6u PFP 
100A. The Kinetex column had the dimensions of 75mm in length and 2.1mm in
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diameter. The LC-MS instrument is pictured in Figure 2. 
 
Figure 2. Liquid Chromatography- Mass Spectrometer 
Used in Study Shimadzu LC-MS 8030 system in the 
Oklahoma State Bureau of Investigation Laboratory 
3.3 Materials 
 Methanol (OmniSolv) and acetonitrile were both LCMS grade; formic acid was 
ACS grade. Ammonium acetate was obtained in solid form. UltraPure water was 
obtained from a Millipore Water Purification System (Synergy, Thermo Scientific). Drug 
standards (6-acetylmorphine, 6-acetylmorphine-D6, codeine, codeine-D6, hydrocodone, 
hydrocodone-D6, hydromorphone, hydromorphone-D3, morphine, morphine-D6, 
oxycodone, oxycodone-D6, oxymorphone and oxymorphone-D3) were purchased from 
Cerilliant (Cerilliant Corporation, Round Rock, TX). Listed in Table 1 are the 
concentrations and solvents for the drug standards as obtained from Cerilliant.  
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Table 1: Drug Standards Used in Study 
 Concentration Solvent 
6-Acetylmorphine 1.0 mg/ml 1 ml Methanol 
6-Acetylmorphine-D6 (internal 
standards) 
1.0 mg/ml 1 ml Methanol 
Codeine 1.0 mg/ml 1 ml Methanol 
Codeine-D6 (internal standards) 1.0 mg/ml 1 ml Methanol 
Hydrocodone 1.0 mg/ml 1 ml Methanol 
Hydrocodone-D6 (internal 
standards) 
1.0 mg/ml 1 ml Methanol 
Hydromorphone 1.0 mg/ml 1 ml Methanol 
Hydromorphone-D3 (internal 
standards) 
1.0 mg/ml 1 ml Methanol 
Morphine 1.0 mg/ml 1 ml Methanol 
Morphine-D6 (internal standards)  1.0 mg/ml 1 ml Methanol 
Oxycodone 1.0 mg/ml 1 ml Methanol 
Oxycodone-D6 (internal standards)  1.0 mg/ml 1 ml Methanol 
Oxymorphone 1.0 mg/ml 1 ml Methanol 
Oxymorphone-D3(internal 
standards) 
1.0 mg/ml 1 ml Methanol 
 
3.4 Preparation of Standards 
3.4.1 Dilute and Shoot sample preparation  
For the qualitative analysis, a multi-drug standard containing 6-acetylmorphine, 
codeine, hydrocodone, hydromorphone, morphine, oxycodone, and oxymorphone was 
prepared at a 10 μg/ml concentration using Cerilliant drug standards diluted in 
acetonitrile. The 10 g/ml qualitative multi-drug standard was made up by combining 
100 µl of each 1 mg/ml opiate standard to a 10 ml volumetric and filling to the line with 
acetonitrile. A multi-drug internal standard containing the seven internal standards (6-
acetylmorphine-D6, codeine-D6, hydrocodone-D6, hydromorphone-D3, morphine-D6, 
oxycodone-D6, and oxymorphone-D3) were prepared at 15 ng/ml, using Cerilliant drug 
standards diluted in acetonitrile. First, a 1.0 µg/ml internal standard mix was made up by 
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adding 10 µl of each 1.0 mg/ml internal standard to a 10 ml volumetric and filling to the 
line with acetonitrile. Next, 3.75 ml of the 1.0 µg/ml internal standard mix was added to a 
250 ml volumetric and filling to the line with acetonitrile to make the 15 ng/ml multi-
drug internal standard. 
For quantitative analysis, a multi-drug standard containing codeine, hydrocodone, 
morphine, and oxycodone was prepared at a 10 μg/ml concentration using Cerilliant drug 
standards diluted in acetonitrile. The 10 µg/ml quantitative multi-drug standard was made 
up by combining 100 µl of each 1.0 mg/ml opiate standard to a 10 ml volumetric and 
filling to the line with acetonitrile. A multi-drug standard containing the internal 
standards of codeine-D6, hydrocodone-D6, morphine-D6, and oxycodone-D6 were 
prepared at 50 ng/ml and diluted in acetonitrile. First, a 10 µg/ml internal standard mix 
was made up by adding 100 µl of each 1.0 mg/ml internal standard to a 10 ml volumetric 
and filling to the line with acetonitrile. Next, 2.5 ml of the 10 µg/ml internal standard mix 
was added to a 500 ml volumetric and filling to the line with acetonitrile make the 50 
ng/ml multi-drug internal standard. 
 3.4.2  Solid Phase Extraction sample preparation 
 For quantitative analysis, the same 10 µg/ml qualitative multi-drug standard made 
for the quantitative analysis for the D&S preparation method was utilized. A multi-drug 
standard containing the internal standards of codeine-D6, hydrocodone-D6, morphine-
D6, and oxycodone-D6 were prepared at 1.0 μg/ml diluted in acetonitrile. The 1.0 µg/ml 
multi-drug internal standard was made up by adding 10 µl of each 1.0 mg/ml internal 
standard to a 10 ml volumetric and filling to the line with acetonitrile. 
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3.5 Sample Collection 
For the validation of the qualitative and quantitative opiate method using the D&S 
sample preparation method, the OSBI provided drug-free whole blood and blood 
specimens from adjudicated criminal cases for analysis in this study. Pig blood treated 
with 2% w/v of sodium fluoride and 75% w/v potassium oxalate was utilized for the 
comparison of the SPE and D&S sample preparation methods.  
3.6 Method Development on the Liquid Chromatograph-Mass Spectrometer 
3.6.1 Qualitative Opiate Method 
 A qualitative method was developed for the analysis of seven opiates (6-
acetylmorphine, codeine, hydrocodone, hydromorphone, morphine, oxycodone, and 
oxymorphone). 
3.6.1.1 Drug Standard Optimization  
 Each drug standard (6-acetylmorphine, 6-acetylmorphine-D6, codeine, codeine-
D6, hydrocodone, hydrocodone-D6, hydromorphone, hydromorphone-D3, morphine, 
morphine-D6, oxycodone, oxycodone-D6, oxymorphone and oxymorphone-D3) was 
optimized on the mass spectrometer (MS) for identification purposes in analysis. The 
mass-charge ratio (m/z) values of the precursor (Q1) ions were manually inputted into the 
multiple reaction monitoring (MRM) event table and optimized automatically by the MS. 
This allowed for multiple user-defined ion fragments to be monitored. The drug standards 
were analyzed separately at 1.0 μg/ml concentrations and injections of 1.0 µl. Product 
(Q3) ions and voltage of collision energies were manually selected for each drug standard 
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based on sensitivity and selectivity. Table 2 lists the MRMs selected for each drug 
standard.  
Table 2. Multi Drug MS Parameters 
Name Q1 Mass (Da) Q3 Mass 
(Da) 
Q1 Pre 
Bias (volts) 
CE 
(volts) 
Q3 Pre Bias 
(volts) 
6-MAM 328.30 165.00 17 46 17 
 328.30 211.20 17 26 22 
6-MAM-D6 334.10 165.00 17 46 17 
Codeine 300.10 198.80 16 32 20 
 300.10 165.15 16 43 15 
Codeine-D6 306.10 218.00 16 25 22 
Hydrocodone 300.10 198.85 15 30 20 
 300.10 171.00 15 40 20 
Hydrocodone-D6 306.10 202.05 18 35 20 
Hydromorphone 286.10 157.15 15 43 16 
 286.10 184.70 15 35 19 
Hydromorphone-
D3 
289.10 184.95 16 40 15 
Morphine 286.10 165.00 15 45 20 
 286.10 151.00 15 45 20 
Morphine-D6 292.10 153.00 16 50 25 
Oxycodone 316.10 174.90 16 35 14 
 316.10 212.00 16 45 21 
Oxycodone-D6 322.10 304.20 20 40 42 
Oxymorphone 302.10 284.15 15 21 30 
 302.10 226.80 15 29 24 
Oxymorphone-D3 305.00 287.15 10 20 20 
 
3.6.1.2 Liquid Chromatograph Parameters 
 An aqueous mobile phase (Eluent A: 1% formic acid 5 mM ammonium acetate in 
deionized water), as well as an organic mobile phase (Eluent B: 1% formic acid 5 mM 
ammonium acetate in 50:50 Methanol:Acetonitrile) were used to carry the sample 
through the column at an oven temperature of 30°C. The organic mobile phase (Eluent B) 
was increased as a gradient from 5% to 95% over the first 3.25 minutes of the run and 
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then returned to 5% for the remainder of the 4.25 minute run. The sample was injected at 
a volume of 20 μl with a total flow rate of 0.6 ml/min.  
 3.6.2 Quantitative Opiate Method 
 The same liquid chromatograph and mass spectrograph parameters used for the 
qualitative method was used for the quantitative method, except the method only 
included the MRM events for codeine, hydrocodone, morphine, oxycodone, and their 
respective internal standards. 
3.7 Preparation of Samples 
 3.7.1 Qualitative Samples 
 The qualitative samples were fortified at a concentration 10 ng/ml, the proposed 
limit of detection. These samples were made by adding 50 µl of the 10 µg/ml of the 
multi-drug standard (containing all seven opiates) to 5 ml of blood.  
 3.7.2 Quantitative Samples 
 There were seven point calibration curve with concentrations at: 1000, 500, 250, 
100, 50, 25, and 10 ng/ml. There was a high quality control (QC) at 400 ng/ml, a medium 
QC at 200 ng/ml and a low QC at 100 ng/ml concentrations. A 1000 ng/ml working 
blood solution was made up daily for the purpose of generating the calibration curve. The 
working blood solution was made by combining 200 µl o the 10 µg/ml quantitative multi-
drug standard to 1.8 ml of blank blood. Table 3 lists how each calibration level was made 
up. The QCs were made up separately from the calibration curve and were used 
throughout the method validation process. The high QC at 400 ng/ml was created by 
mixing 1.0 ml of the 10 µg/ml quantitative multi-drug standard to25 ml of blood. The 
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medium QC at 200 ng/ml was created by mixing 0.5 ml of the 10 µg/ml quantitative 
multi-drug standard to25 ml of blood. The low QC at 100 ng/ml was created by mixing 
250 µl of the 10 µg/ml quantitative multi-drug standard to 25 ml of blood. 
Table 3. Calibration Curve 
Calibration Level Working Blood 
Solution (µl) 
Blank Blood (µl) Final 
Concentration 
(ng/ml) 
1 500 - 1000 
2 250 250 500 
3 125 375 250 
4 50 450 100 
5 50 950 50 
6 25 975 25 
7 10 990 10 
 
 3.7.3 Dilute and shoot sample preparation 
Samples were extracted using a D&S sample preparation method as described by 
Dahn et al. A 1.0 ml aliquot of cold acetonitrile, spiked at a 50 ng/ml concentration for 
each internal standard (6-acetylmorphine-D6, codeine-D6, hydrocodone-D6, 
hydromorphone-D3, morphine-D6, oxycodone-D6 and oxymorphone-D3), was added to 
test tubes containing 0.5 ml of blood. Test tubes were capped, vortex mixed for 20 
seconds, and centrifuged for 10 minutes at 2550 x G (Sorvall T3 centrifuge, Thermo 
Scientific). Approximately 200 μl of the organic phase was transferred to a clean tube and 
was evaporated to dryness under a steady stream of nitrogen. The sample was 
reconstituted in 100 μl of UltraPure water, briefly vortex mixed and transferred to an 
autosampler vial.[8]
8 
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3.7.4 Solid Phase Extraction 
The SPE was adapted to the method developed from the SPEware Corporation 
(Baldwin, Ca) protocol titled “Extraction of Opiates from Whole Blood: For GC or 
GC/MS Confirmations”. The protocol called for Trace-B35 mg, TB-335 extraction 
columns. Approximately 1.0 ml of 100 mM phosphate buffer, at pH=6.0, was added to a 
0.5 ml whole blood sample in a test tube. The sample was vortex mixed for 30 seconds, 
sonicated for 15 minutes, and then centrifuged for 5 minutes at 3000 rpm. The 
supernatant was drawn through the column at a flow of 2-5 ml/minute. The column was 
then washed with 1.0 ml of deionized water, 100 mM of hydrochloric acid, 1.0 ml of 
methanol, and 1.0 ml of ethyl acetate. The column was then dried for 2 minutes at 25 
psig. In a clean test tube, the eluate was collected by using 0.8 ml of ethyl acetate 
containing 2% ammonium hydroxide at 1.0 ml/minute. The eluate was evaporated to 
dryness with a steady stream of nitrogen at 40°C. The sample was reconstituted in 100 μl 
of UltraPure water, briefly vortex mixed and transferred to an autosampler vial. 
3.8 Method validation 
  3.8.1 Validation of the Qualitative Method 
Validation of the qualitative method utilizing the D&S sample preparation method 
followed the method validation plan for qualitative drug analysis by LC-MS as proposed 
by the OSBI. The LC-MS parameters remained the same for the quantitative method, so 
the data from the matrix effect study from the qualitative method was utilized.  
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3.8.1.1 Selectivity and Sensitivity 
Selectivity of a method is determined by evaluating the extent of interference 
caused by endogenous and exogenous compounds. To evaluate the interference of 
endogenous compounds multiple sources of blank matrix were analyzed. Twenty sources 
of blank matrix (old case samples that were to be destroyed) were obtained. One aliquot 
from each blank matrix was analyzed without the addition of any drug standard and one 
aliquot from each blank matrix was spiked at the LOD (10 ng/ml), but without the 
internal standard. The absolute peak area for each of the twenty blanks was compared to 
the mean peak areas of the twenty LOD samples. The method was considered free from 
matrix interference if the peak area in each blank is less than 20% of the mean LOD peak 
area.  
To evaluate the interference of exogenous compounds, the possibility of carryover 
must be determined. A blank matrix sample spiked to a high concentration 
(approximately the high therapeutic concentration) and a blank matrix sample were 
prepared and analyzed one after the other. The method was deemed free from carryover if 
the analyte peak area of the blank matrix sample is less than one-half of the mean LOD 
peak area.  
3.8.1.2 Limit of Detection 
 The LOD is the lowest amount of a drug analyte that can be differentiated from 
any noise present in a blank matrix. The LOD may be the lowest amount that can be 
detected at a level greater than or equal to 3 times the noise in a blank matrix or it may be 
administratively set.   If administratively set, the LOD must be determined over a course 
of multiple days, and may be chosen as the lowest calibrator in a quantitative method. 
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The LOD may also be calculated by using data generated from multiple runs of linear 
calibration models. The standard deviation of the y-intercepts from each calibration 
model and the mean average of the slopes from each calibration model are first 
determined and then used in the following equation: 
LOD = (3.3 x SDYint) / mean 
 For this method, the LOD concentration for the qualitative method was 
administratively set at 10 ng/ml. The LOD was evaluated in at least five different runs. In 
each run, ten replicate aliquots were spiked at 10 ng/ml of the multi-drug standard and 15 
ng/ml of the multi-drug internal standard, followed by sample preparation and analysis on 
the LC-MS. In order for the LOD to be accepted, the mean signal for each run must be 
greater than five times the mean blood blank signals that were determined in the 
selectivity study. [23] 
3.8.1.3 Matrix Effects 
 Ion suppression or ion enhancement may occur in LC-MS methods due to co-
eluting compounds. Two concentrations were evaluated for matrix effects; one 
concentration is at two times the LOD (20 ng/ml) and the other is ten times the LOD (100 
ng/ml). Set 1 consists of the injection solvent (1% formic acid 5 mM ammonium acetate 
in deionized water) spiked at the appropriate concentration and analyzed a minimum of 
six times each. Set 2 consists of samples from twenty sources which are spiked to the 
appropriate concentration, extracted and then analyzed. The responses within each set 
were averaged. The coefficient of variation (CV) was calculated to evaluate the 
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variability of peak area for each concentration. The coefficient of variation should be less 
than 15% at each concentration.  
  3.8.1.4 Co-Administered Drugs 
 To evaluate whether other drugs reasonably expected to be present in a sample 
will cause interference with the opiates analyzed, high concentrations of other drugs were 
analyzed. Each opiate was analyzed at a concentration of 1 ug/ml, which far exceeds the 
expected concentration of an authentic sample. A 1 ug/ml benzodiazepine solution was 
analyzed, containing the following benzodiazepines: zolpidem, alprazolam, diazepam, 
nordiazepam, flurazepam, temazepam, oxazepam, flunitrazepam, midazolam, lorazepam 
and clonazepam. Another solution containing 1 ug/ml of drugs from various drug classes 
was analyzed as well. The solution contained: methamphetamine, 3,4-MDMA, 
acetaminophen, ibuprofen, diphenhydramine, delta-9-THC, 9-carboxy-11-nor-delta-9-
THC and caffeine. The responses observed must be less than 20% of the mean LOD 
signal from the selectivity study for an acceptable performance in light of co-
administered drugs.   
 3.8.2 Validation of Quantitative Method 
 Validation of the opiate sample preparation method for the analysis of morphine, 
codeine, oxycodone, and hydrocodone followed the suggested protocol for validating 
quantitative methods at the OSBI. The data generated from the selectivity and sensitivity, 
limit of detection, and matrix effects was included in validating the quantitative method. 
Additional analyses were conducted to prove the specificity and stability of the 
calibration curve.  
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  3.8.2.1 Accuracy  
 Five consecutive runs were conducted; each run included the sample preparation 
of the seven point calibration curve and two quality controls, followed by analysis on the 
LC-MS. The % error was calculated to evaluate the closeness of the calibrator (1000, 
500, 250, 100, 50, 25, and 10 ng/ml), high QC (400 ng/ml), and low QC (100 ng/ml) to 
the true value. The method was considered to be sufficiently accurate if the ratios were 
within 20%.  
3.8.2.2 Limit of Quantitation 
 The LOQ is the lowest amount of a drug analyte that can be accurately measured 
and is typically set at the lowest calibrator. The LOQ may be the lowest amount that can 
be quantitated at a level greater than or equal to 10 times the noise in a blank matrix. The 
LOQ may also be calculated by using data generated from multiple runs of linear 
calibration models. The standard deviation of the y-intercepts from each calibration 
model and the mean average of the slopes from each calibration model are first 
determined and then used in the following equation: 
LOQ = (10 x SDYint) / mean 
 While the LOQ was administratively set as the same concentration as the LOD at 
10 ng/ml, data from the accuracy study was utilized to calculate the LOQ.  
3.8.2.3 Precision 
 Precision was evaluated to measure the repeatability of several measurements of 
the same sample. The high (400 ng/ml), medium (100 ng/ml), and low (20 ng/ml) quality 
control were analyzed in replicates of six over the course of five runs. Using the 
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calculated means, the within-run precision and between-run precision was calculated for 
each opiate analyte at each concentration. The method was considered to be 
sufficiently precise if the within-run and between-run percentages were within 20%.   
3.8.2.4 Benchtop Stability 
 Benchtop stability was evaluated to determine whether analytes degrade while 
sitting in unrefrigerated conditions during sample preparation. Six replicates of both high 
and low quality controls were prepared and analyzed quickly. Meanwhile, sufficient 
volumes of both the high and low quality controls were left on the countertop for 4 hours. 
After the four hours, 6 replicates of both high and low quality controls were prepared and 
analyzed. The acceptable ratio of mean responses of the room temperature and samples to 
the refrigerated samples was between 85 and 115%.  
  3.8.2.5 Processed Sample Stability 
 Processed sample stability was evaluated to determine the stability of processed 
samples as they sit in the autosampler tray while awaiting analysis on the LC-MS. Ten 
replicates of both the high and low quality controls were prepared, the remaining 
reconstitutes were pooled together at the end (high and low quality controls still 
separate). The pooled extracts were then divided into nine autosampler vials and placed 
into the autosampler tray. Over a 24 hour period, these samples were evaluated in 
triplicates, meaning three injections per vial, at three hour increments (0, 3, 6, 9, 12, 15, 
18, 21 and 24 hours). The data was plotted as the ratio of the analyte area to internal 
standard area versus time. Slopes at zero were desired, but values between -0.01 to 0.01 
indicated processed sample stability up to 24 hours.  
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3.9 Comparison of Sample Preparation Results 
 For both the D&S and SPE sample preparation method, six consecutive runs were 
conducted with each run including the seven point calibration curve and a blank, 
followed by quantitative analysis on the LC-MS. The ratio of the averages of the drug 
standards to the internal standards was calculated. The accuracy and precision of both 
sample preparation methods were compared. 
3.10 Statistical Analysis 
 All statistical analyses were performed using Microsoft Excel 2007 and GraphPad 
Prism®.
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CHAPTER IV 
 
 
RESULTS 
 
4.1 Method development 
 Before the Dahn et al. sample preparation method was considered for validation at 
the OSBI, other sample preparation methods were attempted and abandoned due to poor 
area counts or poor protein cleanup. The same column (Kinetex 2.6u PFP 100A) was 
utilized. The eluents were 5 mM ammonium acetate and 50:50 methanol: acetonitrile.  
4.1.1 Dilute and shoot sample preparation 
 A simple D&S sample preparation was first attempted. A 3.0 ml solution of a 
49:49:2 hexane: ethyl acetate: ammonium hydroxide was added to a 1.0 ml of blood. The 
sample was vortex mixed for 10 minutes and centrifuged for 5 minutes. The supernatant 
was evaporated under a steady stream of nitrogen. The sample was reconstituted in a 20 
µl of methanol and 80 µl of the running buffer (5 mM ammonium acetate), vortex mixed 
and transferred to an injection vial.  
The chromatogram of the first sample prepared with the D&S method is seen in Figure 3.
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The injection amount, the amount the sample was reconstituted in (from 100 µl to 
50 µl), dwell scanning times, and the time-program on the LC-MS were modified in 
attempt to get better results. Figure 4 displays the chromatogram of a D&S prepared 
sample, after the changes.  
When run in replicates, there were issues with the column clogging, retention 
times shifting when not all of drug analytes moved off the column. Figure 5 displays a 
chromatogram of the fifth 10 ng/ml sample replicate in a run of ten replicates. After 
changes to the time program, the replicates were reanalyzed but the column clogged 
(Figure 6) before all ten samples were analyzed. The area counts of the first sample 
analyzed and the fifth sample analyzed are listed in Table 4. 
 
Figure 3. 500 ng/ml dilute and shoot chromatogram 
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Figure 4. 10 ng/ml dilute and shoot sample chromatogram after method 
modification 
 
Figure 5. 10 ng/ml dilute and shoot sample chromatogram, fifth replicate analyzed  
 
Figure 6. 10 ng/ml dilute and shoot sample chromatogram, fifth replicate reanalyzed 
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Table 4. Dilute and shoot replicate areas 
Drugs Rep 1 Area Rep 5 Area 
Morphine 3147 505 
Oxymorphone 27714 113 
Hydromorphone 260 - 
Codeine 8806 142 
Oxycodone 384205 423 
6-MAM 18084 852 
Hydrocodone 31642 53346 
 
4.1.2 Application of syringe and centrifugal filters 
Syringe and centrifugal filters were applied to the D&S method in an attempt to 
clean up the samples and prevent clogging. A syringe filter was used to filter the 
supernatant after vortex mixing and centrifugation. The filtered sample was then 
evaporated under a steady stream of nitogren. Figure 7 displays a chromatogram of the 10 
ng/ml sample. A 0.2 µm nylon membrane centrifugal filter was used to clean up 
supernatant after vortex mixing and centrifugation. The filtered sample was then 
evaporated under a steady stream of nitrogen. Figure 8 displays a chomratogram of the 10 
ng/ml sample. A 0.2 µm nylon membrane centrifugal filter was used to clean up the 
sample after the dry-down with nitrogen and reconstitution. The sample was then 
transferred to an injection vial. Figure 9 displays a chromatogram of the 10 ng/ml sample. 
All attempts lacked the sensitivity desired, so a different method was employed to 
determined if it produced more sensitive results. 
38 
 
 
 
Figure 7. Chromatogram of a sample prepared with syringe filter 
 
Figure 8.Chromatogram of a sample prepared with a centrifugal filter before dry-
down with nitrogen 
 
Figure 9. Chromatogram of a sample prepared with a centrifugal filter after dry-
down with nitrogen and reconstitution 
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4.1.3 Bouzas et al. dilute and shoot sample preparation 
A D&S method was adapted from Bouzas et al. A 200 µl 4:1 methanol: zinc 
sulphate (0.1 M) solution was added to a 100 µl blood sample. The sample was vortex 
mixed and centrifuged for 10 minutes. The supernatant was then evaporated under a 
steady stream of nitrogen and resuspended in 100 µl of the running buffer (5 mM 
ammonium acetate).[19] Ten microliters was injected onto the LC-MS, this amount was 
later increased to 50 µl. The sample volume was also increased to 0.5 ml and the 4:1 
solution was increased to 1.0 ml. The peaks signals were too low and blended in with the 
background noise (Figure 10).  
 
Figure 10. Chromatogram of a 10 ng/ml sample prepared with Bouzas et al. 
protocol 
4.1.4 In-house gas chromatography-mass spectrometry sample preparation 
An in-house (OSBI) opiate sample preparation protocol for analysis on the gas 
chromatography-mass spectrometry (GC-MS) produced promising results. Whole blood 
sample was diluted with 4.0 ml of deionized water and vortex mixed. The blood matrix 
was transferred to an Ultra-15 ultra-filtration tube and centrifuged for 15 minutes at 
2550G. The ultrafiltrate sample was transferred to a ToxiLab-A tube and rotated for 20 
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minutes and centrifuged for 10 minutes. The supernatant was then evaporated under a 
steady stream of nitrogen and resuspended in 50 µl of the running buffer. A 
chromatogram of a 10 ng/ml sample is seen in Figure 11. The area counts for a 10 ng/ml 
sample are seen in Table 5.  
 
Figure 11. Chromatogram of a 10 ng/ml sample prepared using the GC-MS opiate 
protocol 
 
Table 5. In-house GC-MS method  
Drug Area  
Morphine 3456 
Oxymorphone 64254 
Hydromorphone 7382 
Codeine 2074 
Oxycodone - 
6-MAM 2537 
Hydrocodone - 
 
4.1.5 Dahn et al. sample preparation 
The Dahn et al. sample preparation method was the method selected for the analysis of 
opiates and was approved to undergo a method validation study. There was a time 
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program change and an eluent change to 0.1% formic acid, 5 mM ammonium acetate in 
deionized water and 5 mM ammonium acetate in 50:50 methanol: acetonitrile.  
4.2 Qualitative Analysis Method Validation 
 4.2.1 Selectivity and Sensitivity 
 Twenty sources of blank matrix were prepared using the D&S sample preparation 
method. All sources showed no response for any of the seven opiates analyzed in the 
method. The same twenty sources were then spiked to 10 ng/ml concentrations for all 
seven opiates, prepared by the D&S method and analyzed by LC-MS. The mean peak 
areas for each opiate in the spiked sources are listed in Table 6. 
Table 6. Mean Peak areas for spiked sources 
Drug Analyte Mean Peak Area of 
Blank Samples 
Mean Peak Area of Spiked 
Samples 
Morphine No response 6321 
Oxymorphone No response 45822 
Hydromorphone No response 19245 
Codeine No response 8574 
Oxycodone No response 16169 
6-MAM No response 14887 
Hydrocodone No response 33169 
 
 To evaluate carryover, a blank matrix was analyzed immediately following the 
analysis of the high concentration sample (1000 ng/ml). No response was seen in the 
matrix blank.  
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 4.2.2 Limit of Detection 
Five separate analytical runs consisting of ten replicates each were analyzed. The 
acceptance criteria was set such that the mean peak area for each run had to be greater 
than five times the mean blood blank signals from the selectivity study. The mean peak 
area, quantitation ratios for each run is seen in Table 7. Table 8. Comparison of LOD 
peak area averages and blank sources lists the peak area averages of each compound for 
the entire LOD study and responses of each compound for the blank sources in the 
selectivity study. 
Table 7. Mean peak areas, quantitation ratios of ten 10ng/ml replicates 
 Day 1 Day 2 Day 3 Day 4 Day 5   
 Mean 
Area 
QR Mean 
Area 
QR Mean 
Area 
QR Mean 
Area 
QR Mean 
Area 
QR AVG STDEV 
Morphine 3770 0.44 3885 0.56 5827 0.59 4145 0.59 1688 0.60 3863 0.07 
Oxymorphone 28282 0.50 27794 0.60 39003 0.59 28521 0.59 15083 0.62 27737 0.05 
Hydromorphone 12196 0.45 12632 0.54 16942 0.58 12610 0.54 5844 0.63 12044 0.07 
Codeine 5379 0.39 5669 0.47 7660 0.47 5530 0.47 2351 0.47 5318 0.04 
Oxycodone 9306 0.27 9377 0.20 14258 0.22 10182 0.21 4497 0.18 9524 0.03 
6-MAM 8591 0.34 9082 0.40 11721 0.42 9363 0.40 3903 0.45 8532 0.04 
Hydrocodone 20894 0.46 20522 0.52 28839 0.55 21310 0.53 8083 0.57 19930 0.04 
 
43 
 
Table 8. Comparison of LOD peak area averages and blank sources 
 Blank sources from 
Selectivity Study 
LOD Peak Area 
Average 
Morphine No response 3863 
Oxymorphone No response 27737 
Hydromorphone No response 12044 
Codeine No response 5318 
Oxycodone No response 9524 
6-MAM No response 8532 
Hydrocodone No response 19930 
 
 4.2.3 Matrix Effects 
 The CV percentages were calculated to evaluate the variability of peak area for 
each concentration (20 ng/ml and 100 ng/ml), and are listed in Table 9. 
Table 9. CV percentages for matrix effects 
 20 ng/ml 100 ng/ml 
Drug % CV Set 1 % CV Set 2 % CV Set 1 % CV Set 2 
Morphine 4.9 8.8 1.9 4.3 
Oxymorphone 8.0 8.7 3.1 13.2 
Hydromorphone 4.0 10.7 8.4 5.0 
Codeine 5.2 14.9 1.4 9.2 
Oxycodone 5.2 11.0 2.2 10.6 
6-MAM 5.0 7.7 3.1 5.1 
Hydrocodone 4.9 7.8 3.8 5.0 
 
 
4.2.4 Co-Administered Drugs 
 The signal response for the compounds analyzed in the co-administered drug 
study is listed in Table 10 and the calculated percentage of the responses to the LOD peak 
areas are listed in Table 11.  
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Table 10. Co-Administered Drugs Area Response 
 Reported Peak Areas 
Solution 
Analyzed 
Morphin
e 
Oxymorphon
e 
Hydro- 
morphon
e 
Codein
e 
Oxycodon
e 
6-
MAM 
Hydrocodon
e 
Morphine 595238 0 0 0 0 0 0 
Oxymorphone 0 4067786 0 0 0 0 0 
Hydromorphon
e 0 0 1758837 0 0 0 0 
Codeine 305 0 66 618726 1317 2144 550 
Oxycodone 0 1809 0 0 587584 0 1033 
6-MAM 1287 0 0 0 0 
80019
5 0 
Hydrocodone 0 0 0 0 0 0 2238311 
Benzo mix 0 0 0 0 1073 0 0 
Drug mix 0 0 0 0 2457 0 0 
 
Table 11. Percentage of response to LOD signal  
  Percentage of response to LOD signal 
Solution 
Analyzed 
Morphine Oxymorphone Hydromorphone Codeine Oxycodone 6-MAM Hydrocodone 
Morphine 9417       
Oxymorphone  8877      
Hydromorphone   9139     
Codeine 5   216 8 14 2 
Oxycodone  4   3634  3 
6-MAM 20     5375  
Hydrocodone       6748 
Benzo mix     7   
Drug mix     15   
 
4.3 Quantitative Analysis Method Validation 
 4.3.1 Accuracy 
 Accuracy of the seven-point calibrator (1000, 500, 250, 100, 50, 25, and 10 
ng/ml), high QC (400 ng/ml), and low QC (100 ng/ml) of each of the four drugs were 
examined and the results are shown in Table 12. Accuracy for the opiate method was 
sufficient in that the calculated calibrator values for morphine, codeine, oxycodone, and 
hydrocodone were all within 10% of their known values. 
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Table 12. Accuracy of calibration curve 
Drug % Error 
1000  
ng/ml 
500 
ng/ml 
250 
ng/ml 
100 
ng/ml 
50  
ng/ml 
25  
ng/ml 
10 
ng/ml 
High 
QC 
Low 
QC 
Morphine 4.2 2.9 3.0 0.6 3.6 2.9 1.7 8.8 3.3 
Codeine 8.5 0.3 1.8 3.9 4.9 3.9 2.8 6.4 5.3 
Oxycodone 8.2 0.0 0.1 3.4 4.2 3.0 2.3 5.0 5.4 
Hydrocodone 10.5 1.9 1.0 1.1 5.2 3.9 2.7 0.0 5.7 
 
 
 4.3.2 Limit of Quantitation 
 For the purposes of opiate analysis in the OSBI laboratory, the LOQ and lowest 
calibrator was set at 10 ng/ml. This calibrator displayed a high degree of accuracy and 
was considered sufficient for reliable concentration analysis. While the LOQ was 
administratively set, further analysis of data from the accuracy study was utilized to 
calculate actual LOQs of the opiates. The calculated LOQs, listed in Table 13, were well 
below 10 ng/ml.  
Table 13.Weighting and calculated LOQ  
Drug Weighting LOQ (ng/ml) 
Morphine 1/x^2 0.0126 
Codeine 1/x^2 0.0135 
Oxycodone 1/x^2 0.0117 
Hydrocodone 1/x^2 0.0120 
 4.3.3 Precision 
 The percentages for the within-run precision are listed in Table 14. The 
percentages for the between-run precision are listed in Table 15. The within-run precision 
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was below 17% for all the opiates at each quality control level. The between-run 
precision was below 12% for all the opiates at each quality control level. 
Table 14. Within-run precision 
  Within-run precision (%) 
Drug  Run 1 Run 2 Run 3 Run 4 Run 5 
Morphine High (400 ng/ml) 6.9 7.7 3.3 1.9 14.0 
 Mid (200 ng/ml) 7.6 5.7 5.9 3.3 4.8 
 Low (100 ng/ml) 17.3 7.4 9.1 3.2 3.0 
Codeine High (400 ng/ml) 6.9 7.2 1.7 2.2 15.8 
 Mid (200 ng/ml) 4.7 8.9 7.0 3.0 2.1 
 Low (100 ng/ml) 2.8 8.6 6.7 2.1 1.7 
Oxycodone High (400 ng/ml) 9.2 8.8 1.9 3.6 10.7 
 Mid (200 ng/ml) 10.9 7.5 6.9 3.2 3.7 
 Low (100 ng/ml) 5.4 4.3 11.2 3.5 4.6 
Hydrocodone High (400 ng/ml) 8.8 9.0 2.2 3.0 14.2 
 Mid (200 ng/ml) 7.0 5.3 4.2 2.2 2.1 
 Low (100 ng/ml) 4.5 9.2 8.9 3.2 2.1 
 
Table 15. Between-run precision 
Drug  Between-run precision (%) 
Morphine High (400 ng/ml) 11.4 
 Mid (200 ng/ml) 6.0 
 Low (100 ng/ml) 9.7 
Codeine High (400 ng/ml) 9.9 
 Mid (200 ng/ml) 6.3 
 Low (100 ng/ml) 6.4 
Oxycodone High (400 ng/ml) 9.9 
 Mid (200 ng/ml) 7.5 
 Low (100 ng/ml) 7.1 
Hydrocodone High (400 ng/ml) 8.8 
 Mid (200 ng/ml) 6.6 
 Low (100 ng/ml) 7.9 
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 4.3.4 Benchtop Stability 
The ratio percentages for the high and low quality controls are listed in Table 16.  
Table 16. Benchtop stability 
 Morphine Codeine Hydrocodone Oxycodone 
High QC (400 
ng/ml) 
106.1% 103.6% 103.0% 101.8% 
Low QC (100 
ng/ml) 
108.4 % 85.8% 104.8% 90.1% 
 
 4.3.5 Processed Sample Stability 
 Over a 24 hour period, already prepared high and low quality controls were 
analyzed on the LC-MS. The data was plotted as the ratio of the analyte area to internal 
standard area versus time (Figure 12 and Figure 13). The trend line and calculated hours 
before a 20% signal decrease of the quantitation ratios for the low and high QC are seen 
in Table 17and Table 18.  
 
Figure 12. Processed sample stability of low quality control 
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Table 17. Trend line of low quality control 
Drug Analyte Trend line equation Hrs at 20% signal 
decrease  
Morphine y = -0.0004x + 0.1941  1515 
Codeine y = 0.0002x + 0.1496  3252 
Oxycodone y = -0.0002x + 0.1902  3049 
Hyrdrocodone y = -0.0007x + 0.2149  836 
 
 
Figure 13. Processed sample stability of high quality control 
 
Table 18. Trend line of high quality control 
Drug Analyte Trend line equation Hrs at 20% signal 
decrease  
Morphine y = -0.0083x + 17.336  1992 
Codeine y = -0.0045x + 13.385  2797 
Oxycodone y = 0.0034x + 16.242  4542 
Hyrdrocodone y = 0.0091x + 18.712  1791 
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4.4Comparison of Sample Preparation Methods  
 4.4.1 Accuracy 
  4.4.1.2 D&S sample preparation 
 Accuracy of the 1000, 500, 250, 100, 50, 25, and 10 ng/ml calibrator of each of 
the four drugs was examined and the results are shown in. Table 19 
Table 19. Accuracy: Dilute and shoot sample preparation 
Drug   %Error     
 1000  
ng/ml 
500 
ng/ml 
250 
ng/ml 
100 
ng/ml 
50  
ng/ml 
25  
ng/ml 
10 
ng/ml 
Morphine 6.3 3.8 0.1 1.5 2.5 3.2 0.6 
Codeine 3.2 4.6 1.7 1.9 7.6 1.5 14.0 
Oxycodone 2.1 4.3 1.9 2.8 5.0 6.0 9.5 
Hydrocodone 5.4 6.0 8.4 5.2 0.2 3.6 10.7 
 
4.4.1.2 SPE sample preparation  
Accuracy of the 1000, 500, 250, 100, 50, 25, and 10 ng/ml calibrator of each of 
the four drugs was examined and the results are shown in Table 20. 
Table 20. Accuracy: Solid Phase Extraction preparation  
Drug   %Error     
 1000  
ng/ml 
500 
ng/ml 
250 
ng/ml 
100 
ng/ml 
50 
 ng/ml 
25  
ng/ml 
10 
ng/ml 
Morphine 0.0 1.0 1.5 3.6 9.9 2.5 9.4 
Codeine 1.5 2.1 2.2 2.7 8.7 1.4 1.9 
Oxycodone 12.9 16.2 9.0 5.1 30.1 14.3 11.5 
Hydrocodone 9.5 15.5 12.2 3.6 33.6 10.2 10.3 
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 4.4.2 Sensitivity  
The LOD and LOQ for both the D&S and SPE sample preparation methods are 
seen in Table 21. A comparison of both sample preparation methods are seen in Figure 
14, Figure 15, Figure 16, and Figure 17.   
Table 21. Weighting, LOD and LOQ for D&S and SPE sample preparation 
  Dilute and Shoot Solid Phase Extraction 
Drug Weighting LOD 
(ng/ml) 
LOQ 
(ng/ml) 
Weighting LOD 
(ng/ml) 
LOQ 
(ng/ml) 
Morphine 1/x^2 0.0073 0.0221 1/x 0.0022 0.0067 
Codeine 1/x^2 0.0101 0.0305 1/x 0.0051 0.0154 
Oxycodone 1/x^2 0.0010 0.0300 1/x^2 0.0044 0.0132 
Hydrocodone 1/x^2 0.0072 0.0217 1/x^2 0.0046 0.0140 
 
 
 
 
Figure 14. Sample preparation comparison graph for morphine 
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Figure 15. Sample preparation comparison graph for codeine 
 
 
 
Figure 16. Sample preparation comparison graph for oxycodone 
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Figure 17. Sample preparation comparison graph for hydrocodone 
  
4.4.3 Dilute and Shoot 
A chromatogram of a sample prepared with the D&S procedure and spiked at 1000 ng/ml 
can be seen in Figure 18.  
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Figure 18. Chromatogram of a 1000 ng/ml prepared with dilute and shoot 
procedure 
4.4.4 Solid Phase Extraction 
A chromatogram of a sample prepared with the solid phase extraction procedure and 
spiked at 1000 ng/ml can be seen in Figure 19.  
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Figure 19. Chromatogram of a 1000 ng/ml prepared with Solid Phase Extraction 
procedure 
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CHAPTER V 
 
 
DISCUSSION 
 
5.1 Method development  
5.1.1 Dilute and shoot sample preparation 
 Based on the chromatograms of the samples prepared with the hexane: ethyl 
acetate: ammonium hydroxide solution, the solution did not adequately separate the drug 
analytes from the protein in blood. Clogging of the column was seen when samples were 
run in replicates. Replicates showed a significant reduction in peak area counts and poor 
peak shape. The retention time of the peaks also shifted forward and there was an 
increase in background noise. By the sixth replicate, the clogged column caused a 
pressure increase high enough to automatically shut off the instrument.  
5.1.2 Application of syringe and centrifugal filters 
The application of syringe and centrifugal filters were added to the D&S method, for 
further clean-up of the samples.  The use of the syringe and centrifugal filters were 
discontinued because there was no improvement in results. The use of centrifugal filters 
was also more labor- intensive. The centrifugal filters held only 0.5ml sample at a time
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and the samples prepared were approximately 4.0 ml. So the time it took to filter one 
sample was quadrupled. The hexane: ethyl acetate: ammonium hydroxide solution melted 
other types of centrifugal filters, so only the 0.2 µm nylon membrane centrifugal filter 
was used.  
5.1.3 Bouzas et al. dilute and shoot sample preparation  
 The Bouzas et al. D&S sample preparation method produced samples that were 
not clean enough for analysis. The method was originally intended for plasma, whole 
blood without the blood cells, which is a cleaner sample compared to whole blood. The 
methanol: zinc sulphate solution was most likely not strong enough to efficiently separate 
the protein from a sample in whole blood.  
5.1.4 In-house gas chromatography-mass spectrometry sample preparation 
The in-house opiate sample preparation for analysis on the GC-MS is an 
established method at the OSBI. Analysis of these prepared samples showed less 
background noise and more consistent peaks than previous sample preparation methods 
produced.  While this sample preparation method produced cleaner and more precise 
results, it was not pursued, due to the costliness of the ultra-filtration tubes and ToxiLab 
tubes.  
5.1.5 Preference for LLE or D&S sample preparation method 
While the OSBI considered using a SPE sample preparation method, the LLE or 
D&S sample preparation method was desired over a SPE sample preparation method. 
This preference was due to the fact that SPE was believed to require more of the analyst’s 
time and effort. Also, the OSBI laboratories did not have a SPE apparatus or the 
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cartridges necessary to carry out a SPE method. Working with items and solutions that 
were readily available in the laboratories sped up the method development process. 
5.2 Qualitative Analysis Method Validation 
 5.2.1 Selectivity and Sensitivity 
 Selectivity was determined by comparing the mean peak areas for the spiked 
sources to the blank sources.  The mean peak areas for each opiate in the spiked sources 
were easily differentiated from the lack of peaks in the blank matrix, demonstrating that 
the method is free from sample matrix interference. In evaluating sensitivity, no response 
was seen in the matrix blank, demonstrating that the method is free from carryover at 
samples with a concentration of 1000 ng/ml or more. The method was considered to be 
selective and sensitive.  
 5.2.2 Limit of Detection 
The OSBI does not pursue DUID cases with opiate levels less than 10 ng/ml due 
to the difficulty in proving driving impairment. So the true LOD was not determined, but 
was administratively set at 10 ng/ml.  
 5.2.3 Matrix Effects 
The method was considered free from matrix effects because all analytes at 20 
and 100 ng/ml produced a CV of less than 15%.The CV of both concentrations for the 
samples in injection solvent were below 9% and the CV of both concentrations for the 
samples in whole blood were below 15%. While there is some occurrence of ion 
enhancement/suppression, the CV percentages are low enough that other validation 
studies, such as LOD and bias, are unaffected.  
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5.2.4 Co-Administered Drugs 
 Most of the unexpected responses for analytes were below 20% of the mean LOD 
signal. The analysis of the 6-MAM sample caused a response for morphine that was 20% 
of the mean LOD signal. Since these samples were injected at high concentrations that far 
exceed what is expected to be present in authentic case samples, the response at 6-MAM 
was considered acceptable. It is unlikely that a case sample containing other common 
drug analytes will cause interference. The method was considered free from co-
administered drug interference. 
5.3 Quantitative Analysis Method Validation 
 5.3.1 Accuracy 
 The calculated calibrator values for morphine, codeine, oxycodone, and 
hydrocodone were all within 10% of their known values. This validation study shows that 
this method accurately quantitates samples and is reliable for the quantitation of case 
samples.  
 5.3.2 Limit of Quantitation 
 Since the OSBI does not pursue cases with opiate concentrations of less than 10 
ng/ml, the LOD was used as the LOQ and was administratively set at 10 ng/ml. The 
calculated LOQs were well below 10 ng/ml, indicating the possibility for a more sensitive 
method with use of a lower calibration curve and further validation. Although 
concentrations lower than 10 ng/ml are not utilized at the OSBI, clinical applications of 
the method may analyze opiates at lower concentrations.  
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 5.3.3 Precision 
 The method was determined to be precise, considering that the within-run and 
between-run precision percentages were all below the suggested percentage of 20%. This 
shows that the quantitative method is capable of consistently analyzing samples 
quantitatively.  
 5.3.4 Benchtop Stability 
All of the mean responses for the high QC fall within the range of 85 and 115%. 
This indicates that samples on the benchtop remain stable for up to four hours.  
 5.3.5 Processed Sample Stability 
 The plotted ratios of the high and low QC showed fairly flat trend lines with all 
slopes falling between -0.01 to 0.01. Samples that have been left on the LC-MS overnight 
are in stable enough conditions that analysis is reliable up to 24 hours after the sample is 
prepared. Using the trend line to calculate hours of stability up to 20% signal decrease in 
samples, these samples have potential to remain stable for much longer than 24 hours. 
Before these times are put into practice, they must first be studied and revalidated. 
5.4 Comparison of Sample Preparation Methods  
 5.4.1 Accuracy 
The calculated calibrator values for the D&S samples were within 14% of their 
known values for all drug compounds. All, except two of the calculated calibrator values 
for the SPE samples were within 16% of their known values. The 50 ng/ml calibrator for 
oxycodone and hydrocodone were within 33% of their known values. The high deviation 
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for just one of the calibrators, suggests a possible error when preparing the calibrators or 
is possibly due to an unfamiliarity to the SPE preparation method.  
 5.4.2 Sensitivity  
The LOD and LOQ were calculated for both the D&S and SPE method to 
determine sensitivity. The SPE method was found to be more sensitive than the D&S 
method. The LOD calculated for the D&S method was 0.010 ng/ml and 0.005 ng/ ml for 
the SPE method. The LOQ calculated for the dilute and shoot method was 0.030 ng/ml 
and 0.015 ng/ml for the SPE method. Plotted quant ratios and chromatograms show that 
the SPE method produced higher peak areas than the D&S method. The calculated LOQs 
are theoretical values and would have to be proven with a series of calibration curves. 
5.4.3 Price comparison 
The price of a making up a SPE and a D&S sample was calculated (Table 22 ) 
based on the cost of solvents, materials, glassware, and analyst’s time. The cost of 
making up a D&S samples is approximately 1/3 the cost of making up a SPE sample. The 
major expenses for the SPE samples are due to the use of extra solvents and a cartridge, 
but mostly due to the cost of the analyst’s time. It takes roughly 2 hours to prepare a 
sample using the SPE sample preparation method, while the D&S sample preparation 
takes roughly 45 minutes.  
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Table 22. Sample cost comparison 
 SPE D&S 
Solvents/materials $4.35 $0.07 
Glassware $1.87 $1.87 
Analyst's time $52.00 $21.44 
Total Cost $58.22 $23.37 
 
5.5 Comparison to other studies 
 There is a lack of studies over D&S sample preparation methods for the 
quantitative analysis of opiates in blood samples in the literature. But there several SPE 
sample preparation methods which are comparable to the SPE sample preparation method 
utilized for this study. The LOD’s and LOQ’s found in the literature were considerably 
lower than the administratively set LOD and LOQ of 10 ng/ml for the validation 
study.[2] The LOD for opiates were as low as 0.5 and 1.0 ng/ml and the LOQ for opiates 
were as low as 1.0 and 2.0 ng/ml. One study determined the LOD of codeine as 0.0002 
mg/kg and the LOD of morphine as 0.0001 mg/kg.[24] The LLOQ of codeine was 0.0025 
mg/kg and the LLOQ of morphine and 0.0025 mg/kg.[25] While these numbers are lower 
than the administratively set LOD and LOQ, they are quite close to the calculated LOD 
and LOQ values which were as low as 0.0022 ng/ml for the LOD and 0.0132 ng/ml for 
the LOQ. 
5.6 Significance 
Not many studies have extensively compared the results of different sample 
preparation methods using the same analytical method on the LC-MS, but there is 
agreement in that the SPE method produces cleaner samples which will then produce 
more accurate and sensitive results. While the results were in agreement that the SPE 
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sample preparation method has better sensitivity, the D&S method appeared to produce 
more accurate results. It is possible that since the analytical method created on the LC-
MS was created for D&S samples, the LC-MS method was more specific to the analysis 
of D&S methods than the SPE samples.  
5.7 Future work 
Future work that could be included with this study, is adding another sample 
preparation method for the analysis of opiates. The resulting data would give more 
insight into how different sample preparation methods affect analytical results. Also, 
changing components of the LC/MS/MS analysis such as column type, eluent type or 
injection amount could show the importance of choosing a certain brand or type for the 
analysis of opiates.  
Another study that could be conducted involves the comparison of sample 
preparation methods for the analysis of another drug class altogether. This study would 
give insight into how efficient the sample preparation methods are at extracting the drug 
analyte and how the sample preparation methods affect analytical results. 
5.8 Conclusion 
 The comparison of the SPE and D&S sample preparation methods yielded results 
that were mostly expected from the literature, in that the SPE sample preparation method 
produced more sensitive results than the D&S method. Since the use of a column and 
multiple steps of solvent-washing of samples in the SPE typically produce cleaner result, 
it was unexpected that the D&S method produced more accurate results than the SPE 
method.  
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Data generated from the validation studies for the qualitative and quantitative 
method demonstrate a reliable and accurate dilute and shoot sample preparation method 
for the opiate analysis. While the comparison data shows that the SPE is the better sample 
preparation method for the analysis of opiates, the D&S method also produces results 
which are accurate and reliable for use in government crime labs. 
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